TNFRSF10A
Reaktivität: Human
FACS, IHC
Wirt: Maus
Monoclonal
TR1-02
unconjugated
Applikationshinweise
Western Blot (1/500-1/1000). Immunohistochemistry on Paraffin Sections (5 μg/mL). Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1.0 mg/mL
Buffer
PBS, 0.02 % Sodium Azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer. Dilute only prior to immediate use.
Target
TNFRSF10A
(Tumor Necrosis Factor Receptor Superfamily, Member 10a (TNFRSF10A))
Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel death domain containing receptor was recently identified and designated DR4 (for death receptor 4)1. The ligand for this novel death receptor has been identified and termed TRAIL, which is a new member in the TNF family. DR4 is also called TRAIL receptor-1 (TRAIL-R1). DR4 is expressed in most of human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. Like TNFR1, Fas and DR3, DR4 mediates apoptosis and NF-kB activation in many tissues and cells.Synonyms: APO2, DR4, Death receptor 4, TNF-related apoptosis-inducing ligand receptor 1, TNFRSF10A, TRAIL receptor 1, TRAIL-R1, Tumor necrosis factor receptor superfamily member 10A